University of Pittsburgh had begun immunization experiments in monkeys using dead polio virus. Soon, however, Salk began to test inoculations in paralyzed polio patients and by 1953 human trials among the general population were initiated. By the spring of the following year, the largest controlled field trials in medical history were underway, and by 1955 the vaccine developed by Salk and his researchers was declared effective. By 1962, Salk's vaccine had reduced the incidence of polio in the United States by 95 percent. The breakthroughs in immunology and vaccine development at Pitt by Salk and his team are considered one of the most
SAV001 a feasible option for an HIV vaccine. Indeed, Jonas Salk developed a therapeutic HIV vaccine in 1987, called Remune now being developed by Immune Response BioPharma, Inc., is based on the killed whole virus approach. Remune vaccine has completed over 25 clinical studies to date and showed a robust mechanism of action restoring white blood cell counts in CD4 & CD8 T cells by reducing viral load and increasing immunity. Also, a group of researchers and professionals in the field of HIV strongly advocates that the killed HIV approach must be taken to fight back the global HIV and AIDS